The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Histone deacetylase 3 (HDAC3) is a potential target for the treatment of human diseases such as cancers, diabetes, chronic inflammation and neurodegenerative diseases. Previously, we proposed a virtual screening (VS) pipeline named “Hypo1_FRED_SAHA-3” for the discovery of HDAC3 inhibitors (HDAC3Is) and had thoroughly validated it by theoretical calculations. In this study, we attempted to explore its practical utility in a large-scale VS campaign. To this end, we used the VS pipeline to hierarchically screen the Specs chemical library. In order to facilitate compound cherry-picking, we then developed a knowledge-based pose filter (PF) by using our in-house quantitative structure activity relationship- (QSAR-) modelling approach and coupled it with FRED and Autodock Vina. Afterward, we purchased and tested 11 diverse compounds for their HDAC3 inhibitory activity in vitro. The bioassay has identified compound 2 (Specs ID: AN-979/41971160) as a HDAC3I (IC50 = 6.1 μM), which proved the efficacy of our workflow. As a medicinal chemistry study, we performed a follow-up substructure search and identified two more hit compounds of the same chemical type, i.e. 2–1 (AQ-390/42122119, IC50 = 1.3 μM) and 2–2 (AN-329/43450111, IC50 = 12.5 μM). Based on the chemical structures and activities, we have demonstrated the essential role of the capping group in maintaining the activity for this class of HDAC3Is. In addition, we tested the hit compounds for their in vitro activities on other HDACs, including HDAC1, HDAC2, HDAC8, HDAC4 and HDAC6. We have identified these compounds are HDAC1/2/3 selective inhibitors, of which compound 2 show the best selectivity profile. Taken together, the present study is an experimental validation and an update to our earlier VS strategy. The identified hits could be used as starting structures for the development of highly potent and selective HDAC3Is.
Overview
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
LIBSVM: A library for support vector machines
Chang, C.-C., & Lin, C.-J. (2011) · ACM Transactions on Intelligent Systems and Technology · doi:10.1145/1961189.1961199 · Cited by 40,918
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Parr, R. G., Szentpály, L. V., & Liu, S. (1999) · Journal of the American Chemical Society · doi:10.1021/ja983494x · Cited by 7,465
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
Hawkins, P. C. D., Skillman, A. G., Warren, G. L., Ellingson, B. A., & Stahl, M. T. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100031x · Cited by 1,607
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · cited 1×
“(3) Due to the substitution of 2-methylallyl-oxyl group at the ortho-position, the core scaffold of compound 2–3, i.”
BackgroundHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances
Lionta, E., Spyrou, G., Vassilatis, D., & Cournia, Z. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666140929124445 · Cited by 1,165
FRED Pose Prediction and Virtual Screening Accuracy
McGann, M. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci100436p · Cited by 764
Conceptual Density Functional Theory and Some Recent Developments
Shu-Bin, L., Research Computing Center, U. O. N. C., & Research Computing Center, U. O. N. C. (2009) · Acta Physico-Chimica Sinica · doi:10.3866/pku.whxb20090332 · Cited by 512
HDAC3 Is a Critical Negative Regulator of Long-Term Memory Formation
McQuown, S. C., Barrett, R. M., Matheos, D. P., Post, R. J., Rogge, G. A., Alenghat, T., Mullican, S. E., Jones, S., Rusche, J. R., Lazar, M. A., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5052-10.2011 · Cited by 507
McGann, M. R., Almond, H. R., Nicholls, A., Grant, J. A., & Brown, F. K. (2003) · Biopolymers · doi:10.1002/bip.10207 · Cited by 491
HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis
Saha, R. N., & Pahan, K. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401769 · Cited by 441
Computer Aided Drug Design: Success and Limitations
Hassan Baig, M., Ahmad, K., Roy, S., Mohammad Ashraf, J., Adil, M., Haris Siddiqui, M., Khan, S., Amjad Kamal, M., Provazník, I., & Choi, I. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151125000550 · Cited by 424
Comparison of Topological, Shape, and Docking Methods in Virtual Screening
McGaughey, G. B., Sheridan, R. P., Bayly, C. I., Culberson, J. C., Kreatsoulas, C., Lindsley, S., Maiorov, V., Truchon, J.-F., & Cornell, W. D. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci700052x · Cited by 417
Chen, X., Barozzi, I., Termanini, A., Prosperini, E., Recchiuti, A., Dalli, J., Mietton, F., Matteoli, G., Hiebert, S., & Natoli, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121131109 · Cited by 397
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner
Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J. R., & Wood, M. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213364110 · Cited by 395
Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus
Christensen, D. P., Dahllöf, M., Lundh, M., Rasmussen, D. N., Nielsen, M. D., Billestrup, N., Grunnet, L. G., & Mandrup-Poulsen, T. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00021 · Cited by 261
Targeting the pancreatic β-cell to treat diabetes
Vetere, A., Choudhary, A., Burns, S. M., & Wagner, B. K. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4231 · Cited by 252
Histone Acetylation Modifiers in the Pathogenesis of Malignant Disease
Mahlknecht, U., & Hoelzer, D. (2000) · Molecular Medicine · doi:10.1007/bf03402044 · Cited by 180
Jia, H., Pallos, J., Jacques, V., Lau, A., Tang, B., Cooper, A., Syed, A., Purcell, J., Chen, Y., Sharma, S., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.016 · Cited by 169
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia · doi:10.1038/leu.2013.231 · Cited by 159
Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation
Leus, N. G., Zwinderman, M. R., & Dekker, F. J. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.06.019 · Cited by 150
Jia, H., Kast, R. J., Steffan, J. S., & Thomas, E. A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds379 · Cited by 143
Structure-Based Virtual Ligand Screening: Recent Success Stories
Villoutreix, B., Eudes, R., & Miteva, M. (2009) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620709789824682 · Cited by 139
Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells
Larsen, L. H., Tonnesen, M., Rønn, S. G., Størling, J., Jørgensen, S. W., Mascagni, P., Dinarello, C. A., Billestrup, N., & Mandrup-Poulsen, T. R. (2007) · Diabetologia · doi:10.1007/s00125-006-0562-3 · Cited by 132
Leus, N. G. J., van der Wouden, P. E., van den Bosch, T., Hooghiemstra, W. T. R., Ourailidou, M. E., Kistemaker, L. E. M., Bischoff, R., Gosens, R., Haisma, H. J., & Dekker, F. J. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.03.010 · Cited by 131
HDAC3 Is a Negative Regulator of Cocaine-Context-Associated Memory Formation
Rogge, G. A., Singh, H., Dang, R., & Wood, M. A. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4472-12.2013 · Cited by 126
Felice, C., Lewis, A., Armuzzi, A., Lindsay, J. O., & Silver, A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13008 · Cited by 120
Lewis, E. C., Blaabjerg, L., Størling, J., Rønn, S. G., Mascagni, P., Dinarello, C. A., & Mandrup-Poulsen, T. R. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00152 · Cited by 117
Jia, H., Morris, C. D., Williams, R. M., Loring, J. F., & Thomas, E. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415195112 · Cited by 115
Khan, S., & Jena, G. (2015) · Epigenomics · doi:10.2217/epi.15.20 · Cited by 102
Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats
Lundh, M., Galbo, T., Poulsen, S. S., & Mandrup‐Poulsen, T. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12470 · Cited by 100
Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes
Sharma, S., & Taliyan, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.009 · Cited by 100
HDAC inhibitors: A new promising drug class in anti-aging research
Pasyukova, E. G., & Vaiserman, A. M. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.008 · Cited by 99
Inhibition of Histone Deacetylase 3 Protects Beta Cells from Cytokine-Induced Apoptosis
Chou, D. H.-C., Holson, E. B., Wagner, F. F., Tang, A. J., Maglathlin, R. L., Lewis, T. A., Schreiber, S. L., & Wagner, B. K. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.05.010 · Cited by 95
Jia, H., Wang, Y., Morris, C. D., Jacques, V., Gottesfeld, J. M., Rusche, J. R., & Thomas, E. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152498 · Cited by 94
Zhang, S., Golbraikh, A., & Tropsha, A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050260x · Cited by 93
Wagner, F. F., Lundh, M., Kaya, T., McCarren, P., Zhang, Y.-L., Chattopadhyay, S., Gale, J. P., Galbo, T., Fisher, S. L., Meier, B. C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00640 · Cited by 86
Christensen, D. P., Gysemans, C., Lundh, M., Dahllöf, M. S., Noesgaard, D., Schmidt, S. F., Mandrup, S., Birkbak, N., Workman, C. T., Piemonti, L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320850111 · Cited by 72
Thomas, E. (2014) · Pharmaceuticals · doi:10.3390/ph7060634 · Cited by 55
Xia, J., Jin, H., Liu, Z., Zhang, L., & Wang, X. S. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500062f · Cited by 53
Self-citationDirice, E., Ng, R. W. S., Martinez, R., Hu, J., Wagner, F. F., Holson, E. B., Wagner, B. K., & Kulkarni, R. N. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.804328 · Cited by 49
Hsieh, J.-H., Yin, S., Wang, X. S., Liu, S., Dokholyan, N. V., & Tropsha, A. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci2002507 · Cited by 41
Self-citationVilladsen, J. S., Stephansen, H. M., Maolanon, A. R., Harris, P., & Olsen, C. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4008449 · Cited by 39
Alaghband, Y., Kwapis, J. L., López, A. J., White, A. O., Aimiuwu, O. V., Al-Kachak, A., Bodinayake, K. K., Oparaugo, N. C., Dang, R., Astarabadi, M., et al. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.09.001 · Cited by 34
Phan, M. L., Gergues, M. M., Mahidadia, S., Jimenez-Castillo, J., Vicario, D. S., & Bieszczad, K. M. (2017) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2017.00065 · Cited by 34
Comparative Modeling and Benchmarking Data Sets for Human Histone Deacetylases and Sirtuin Families
Xia, J., Tilahun, E. L., Kebede, E. H., Reid, T.-E. R., Zhang, L., & Wang, X. S. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci5005515 · Cited by 28
Self-citationA Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors
Hu, H., Xia, J., Wang, D., Wang, X., & Wu, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010137 · Cited by 12
Self-citationXia, J., Hsieh, J., Hu, H., Wu, S., & Wang, X. S. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00749 · Cited by 12
Self-citation
Cited by
Lanka, G., Begum, D., Banerjee, S., Adhikari, N., Yogeeswari, P., & Ghosh, B. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107481 · Cited by 112
Butyrate modulates diabetes-linked gut dysbiosis: epigenetic and mechanistic modifications
Noureldein, M. H., Bitar, S., Youssef, N., Azar, S., & Eid, A. A. (2020) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0132 · Cited by 84
Kumbhar, N., Nimal, S., Barale, S. S., Kamble, S. A., Bavi, R., Sonawane, K. D., & Gacche, R. N. (2022) · Scientific Reports · doi:10.1038/s41598-022-05698-7 · Cited by 41
HDAC3i‐Finder: A Machine Learning‐based Computational Tool to Screen for HDAC3 Inhibitors
Li, S., Ding, Y., Chen, M., Chen, Y., Kirchmair, J., Zhu, Z., Wu, S., & Xia, J. (2020) · Molecular Informatics · doi:10.1002/minf.202000105 · Cited by 33
Self-citationTwo New 1,3,4-Oxadiazoles With Effective Antifungal Activity Against Candida albicans
Capoci, I. R. G., Sakita, K. M., Faria, D. R., Rodrigues-Vendramini, F. A. V., Arita, G. S., de Oliveira, A. G., Felipe, M. S. S., Maigret, B., Mendonca, P., Kioshima, É. S., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02130 · Cited by 36
Metadata
- Authors
- Xia, J., Hu, H., Xue, W., Wang, X. S., & Wu, S.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Howard University (US)
- Corresponding author
- Xia, Jie
- Wu, Song
- Venue
- Journal of Enzyme Inhibition and Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2018-01-01
- Volume
- 33
- Issue
- 1
- Pages
- 525-535
- ISSN
- 1475-6366 (ISSN-L)
- 1475-6374
- PMC
- PMC5978667
- OpenAlex
- W2793548260
- Cited by
- 24
- References
- 52
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 4
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Enzyme Inhibition and Medicinal Chemistry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Fundamental Research Funds for the Central Universities (2016ZX350036)
- National Natural Science Foundation of China (81603027)
- CAMS Innovation Fund for Medical Sciences (2017-I2M-2-004)
- State Administration of Foreign Experts Affairs P.R. China (T2017069)
- District of Columbia Developmental Center for AIDS Research (P30AI087714)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- HDAC3 inhibitors, HDAC3, virtual screening, QSAR models, FRED, AutoDock Vina, capping groups, substructure search, hit identification
- MeSH terms
- Histone Deacetylase 3, Biological Assay, Dose-Response Relationship, Drug, Histone Deacetylases, Humans, Models, Molecular, Molecular Structure, Quantitative Structure-Activity Relationship, Drug Discovery, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.